AstraZeneca Unit Defends Soliris Patent Against Invalidity Bid
Alexion has hit back at a claim by Amgen that its patent over Soliris is invalid, arguing in a London court that the formula for the rare blood disease treatment was...To view the full article, register now.
Already a subscriber? Click here to view full article